

Evaluating the Complexity of Liver Cirrhosis: Current Understanding of Complications, Histopathological Features, and Treatment Options

Aisha S. Patel and Kavita N. Rao

Aisha S. Patel and Kavita N. Rao – Department of Biological Sciences, Tezpur University, Tezpur, Assam, India

ABSTRACT

[Liver](#) is an integral organ in vertebrates. Along with gallbladder, pancreas For Correspondence and intestines it function together to digest, absorb, and to process foods. The liver's main work is to filter the blood coming back from the [alimentary](#) Department of Life Science, [canal](#), before passing it to the remainder of the body. The liver conjointly National Institute of Technology, detoxifies chemicals and metabolizes medicine. The liver secretes digestive Rourkela, Orissa, India. fluid that lands up back within the intestines. The liver conjointly makes proteins vital for blood clotting and different functions. From many liver Keywords: Cirrhosis, Liver which liver gets permanent scarring. [Cirrhosis](#) happens in response to harm Transplantation, Hepatitis liver. Whenever liver is impaired, it tries to repair itself. Within these process, scar tissue forms. As cirrhosis of the liver progresses, additional and additional connective tissue forms, creating tough for the liver to operate.

INTRODUCTION

The prevalence of [chronic liver disease](#) (CLD) continues to rise, particularly with the epidemic of hepatitis and fatness. CLD and liver disease were calculable by the Disease Control and Prevention (CDC) to be the 12th leading reason behind mortality within the USA in 2007 accounting for 29,165 deaths that is 3.4% more than 2006, leading to the 2nd largest share increase of all-cause mortality ^[1]. But, data counsel that liver related mortality is really considerably beyond estimated; a study according it to be 121% beyond CDC estimates, creating CLD the 8th leading reason behind death with in the North American country ^[2]. This review can highlight recent knowledge on the complications of liver disease called cirrhosis.

Cirrhosis is outlined because the microscopic anatomy development of regenerative nodules encircled by fibrous bands in response to chronic liver injury, that ends up in malignant hypertension and last stage disease. Recent advances within the understanding of the past and pathophysiology of cirrhosis of the liver, and in treatment of its complications, leading to improved management, quality of life and expectancy of cirrhotic patients ^[3-8]. At present, [liver transplantation](#) remains the sole curative possibility for a specific cluster of patients, however pharmacologic therapies that may halt progression to decompensated cirrhosis of the liver or perhaps reverse cirrhosis of the liver measure presently being developed. This concise summary focuses on diagnosis, complications and management of cirrhosis of the liver and novel clinical and scientific developments.

Patients with chronic disease, notably liver cirrhosis of the liver, are thought of as a risky cluster for developing [Hepatocellular carcinoma](#) (HCC). HCC is one among the foremost common cancers worldwide. Since the first detection and treatment of HCC is imperative for improvement of the very important prognosis of patients, HCC surveillance work is performed in step with the rules of assorted associations ^[9-13]. [Open access journals](#) in all areas of the field liver, making them freely available through online without any restrictions or any other subscriptions to researchers worldwide and even to the common peoples for awareness. These journals ensures the barrier-free distribution of its content through online open access and thus helps in improving the citations for authors and attaining good [impact factor](#).

[Russian Scientific Liver Society](#) main aim of the society was permanent improvement of care about patients with liver diseases, through increase the knowledge of medical specialists in the area of hepatology. [American Liver Foundation](#) mission is to facilitate, advocate and promote education, support

and research for the prevention, treatment and cure of liver disease. [Canadian liver foundation](#) vision is to have a world without liver disease. Canadian Liver Foundation is a national non-profit organization committed to promoting liver health and providing hope to people living with liver disease through: investing in liver research; sharing the knowledge gained through liver research with the medical community and the public; delivering support programs through committed volunteers; advocating for liver health for all Canadians.

[Journal of Hepatitis](#) is an International scholarly [peer-reviewed journal](#), this Journal Publishes articles in all fields and areas of Hepatology and Liver diseases that considers articles concerned with any aspect of Viral Hepatitis such as Alcoholic hepatitis, Chronic hepatitis and Cholestasis, as well as basic research on Non-alcoholic fatty liver disease. [Journal of Hepatology and Gastrointestinal disorders](#) is one of the best open access journals that aims to publish the most complete and reliable source of information on the discoveries and current developments in the form of original articles, review articles, case reports, short communications, etc. in all areas of the hepatology, gastro-intestinal disorders like constipation, Irritable Bowel Syndrome (IBS) etc. and making them freely available worldwide. [The Journal of Liver](#) addresses both the vital role of the liver in the body and also the infections such as hepatitis, alcohol damage, fatty liver, cirrhosis, drug damage, Liver cancer, Liver function, Liver disease, Liver, Fatty liver disease, Liver function test, Liver transplant, Liver cirrhosis, Wilson's disease, Gallstones symptoms, Hepatocellular carcinoma, Liver inflammation, Hepatocytes. [Journal of Gastrointestinal Cancer and Stromal Tumors](#) deals with the understanding and treating cancers arising in the gastrointestinal tract and its coverage ranges widely across disciplines, clinical trials and outcome studies and publishes novel research related to cancers arising from the gastrointestinal tract.

STAGES OF LIVER DISORDERS

Even with a wide vary of conditions diagnosed as liver illness, the stages and injury to the organ are measure consistent. From the start of the condition to advanced disease, the injury progresses in these four stages:

Stage 1: Initial Stage of liver disease

With any condition inflicting disease, the primary step includes inflammation of the liver or bile duct. This inflammation causes abdominal pain because the body tries to fight the infection or irritation ^[14]. If left untreated, this inflammation will cause injury to the liver, creating the condition worse. During the starting stage, not like some conditions in advanced [disease](#), the symptoms and inflammation is treatable to stop the second step of the illness.

Stage 2: Pathology of the Liver

Many times, symptoms of liver disease aren't recognised till this stage or consequent. Within the [pathology](#) stage, injury or scarring from the primary stage begins to dam the conventional blood flow of the liver ^[15]. During this stage, the liver isn't functioning properly, however through treatment, it's going to be healed and forestall from now on progression of the illness.

Stage 3: Cirrhosis of the Liver

A chronic condition, [liver cirrhosis](#) creates permanent scarring that blocks the blood flow. This dangerous stage causes different serious conditions and symptoms that increase the severity of the disease and is recognized as the leading causes of death within the North American nation. For this stage of the malady, doctors focus treatment on managing the symptoms so as to forestall the foremost advanced disease stage.

Stage 4: Liver Failure and Advanced disease

In the end of the malady, [liver failure](#) signals the end of healthy liver. The patient currently needs immediate medical attention to forestall death. Symptoms of liver failure embody dry heave, diarrhoea and fatigue furthermore because the symptoms from stage three^[16-20]. Whereas the progression from liver disease to failure will take years, the harm is irreversible and ends up in ultimate death.

COMPLICATION OF CIRRHOSIS

Chronic injury to the liver, notwithstanding the cause, ends up in a wounding response that ends up in pathology, and ultimately scarring and replacement of [healthy liver](#) design by regenerative nodules. This method, at the side of the production of endogenous vasoconstrictors like endothelins and production of vasodilators like nitric acid, ends up in a rise in intrahepatic resistance and malignant hypertension. Clinically vital complications of CLD because of malignant hypertension seem to be restricted to things during which the hepaticvenous blood pressure gradient (HVPG) is elevated higher than 10mmHg. Major advances are created in recent years to each stop and treat the common complications of cirrhosis of the liver like variceal haemorrhage, ascites, spontaneous microorganism peritoneal [inflammation](#) and brain disorder^[2128]. It's vital to notice that microorganism infections area unit is frequent, particularly in decompensated cirrhotics, intensifying viscus pathology, brain disorder and malignant hypertension and underlining the necessity for vigilance and rigorous antibiotic treatment in cirrhosis of the liver. Increased microorganism translocation from the gut, a compromised immune operate associate degree an excessive pro-inflammatory cytokine unharness are concerned within the pathologic process of the cirrhosis-associated general inflammatory syndrome^[29]. Associate example is that the failure to regulate musculature variceal haemorrhage with associated microorganism infection^[30-45]. [Shashideep Singhal](#) was one of the professor extensively involved in clinical and translational research in the field of liver diseases. His research has focused on molecular mechanisms and targets in Acute Liver Failure.

ETIOLOGY OF CIRRHOSIS

The etiology of cirrhosis of the liver will sometimes be known by the patient's history combined with serological and histological analysis. Alcoholic disease and viral hepatitis are the foremost common causes within the Western world, whereas viral hepatitis prevails in most elements of Asia and geographical region. When the identification of the viral hepatitis virus in 1989 and of non-alcoholic steatohepatitis (NASH) in corpulent and diabetic subjects, the identification of cirrhosis of the liver is not an evident cause (cryptogenic cirrhosis) isn't created. It's vital to understand the etiology of cirrhosis of the liver, since it will predict complications and direct treatment choices. It conjointly permits the discussion of preventive measures, e.g., with relations of patients with alcoholic cirrhosis of the liver or chronic hepatitis, and thought of (genetic) testing and preventive recommendation for relatives of patients with genetic diseases, like [Wilson's disease](#). Often multiple etiological factors contribute to the event of cirrhosis of the liver, as exemplified in medicine studies that known regular (moderate) alcohol consumption, age on top of fifty years, and male gender as risk factors in chronic viral hepatitis^[46-49], or older age fatness, hypoglycemic agent resistance/type two diabetes disease, high blood pressure and lipoidaemia (all options of the metabolic syndrome) in NASH^[50,51].

[Toru Shizuma](#) has a published article on topic "Pernicious Anaemia in Patients with Primary Biliary Cirrhosis,

Autoimmune Hepatitis, and Chronic Viral Hepatitis" where she has described about the Pernicious Anemia (PA) with Autoimmune Liver Diseases (ALDs) or chronic viral hepatitis in omics's journal. [Nour Elleuch](#) has studied about the Refractory Ascites in Cirrhosis: Prevalence and Predictive Factors.

Liver Biopsis

Diagnostic assay of the liver is a process during which a little quantity of liver tissue is surgically removed thus it is analysed within the laboratory by a medical specialist. Liver biopsies are sometimes done to discover the presence of abnormal cells within the liver, like cancer cells, or to judge malady processes like

liver disease. Doctor mostly prescribes for this check if blood or imaging tests indicate there are issues together with your liver.

Laparoscopic liver diagnostic assay yields additional info than body covering liver diagnostic assay, because it allows gross review of the internal organ surface. Performing arts a diagnostic assay below laparoscopic vision additionally ensures that the tissue cylinders are massive enough for more process within the pathology department ^[52]. The mini-laparoscopic technique with 3-mm trocars (maximum size) makes the procedure safer while not limiting the surgeon's read of the liver, and it additionally allows synchronic review of the serous membrane, spleen, and different intraperitoneal structures ^[53]. In an exceedingly laparoscopic diagnostic assay, the doc will coagulate the puncture web site promptly just in case of visible haemorrhage or gall outpouring. This, in turn, makes it possible to perform liver [biopsies](#) on patients those are at elevated risk of hemorrhage.

Biopsy is taken into account as the main standard for diagnosing of liver cirrhosis, and successive histologic grading of inflammation and staging of pathology will assess risk of progression. However, diagnostic test is at risk of substantial sampling variability all liver diseases ^[54-57]. So once staging pathology in hepatitis C patients victimisation the METAVIR system that is easy and its uses are solely four stages (stage four being cirrhosis), one third of scores differed by a minimum of one stage once a diagnostic test from the left liver lobe was compared thereto from the proper lobe, and with similar results for grading of inflammation ^[58]. In [hepatitis C](#), correct staging was solely achieved for sixty fifth and seventy fifth of cases once biopsies were fifteen millimetre and twenty five millimetre long, severally ^[59], whereas in clinical apply solely Sixteen Personality Factor Questionnaire of biopsies reach 25mm long. Despite these shortcomings, diagnostic test continues to be needed to verify liver disease in patients with remunerated liver operate and to recommend its cause. Diagnostic test confirmation of liver disease isn't necessary once clear signs of liver disease, like pathology, coagulopathy, and a shrunken nodular showing liver area available.

A liver diagnostic test is obtained by an (radiographically-guided) connective tissue, a transjugular or laparoscopical route. A larger risk of hemorrhage following a diagnostic test has been discovered with larger-diameter needles. In suspected [liver disease](#) a cutting is most well-liked over a suction needle, so as to forestall tissue fragmentation ^[60]. A pair of to three % of patients need hospital admission for management of complications; pain or cardiovascular disease area unit the predominant causes. 60% of complications occur at intervals 2, and ninety six at intervals twenty four hours when diagnostic test. Mortality, chiefly to severe haemorrhage is 1 in 10,000 to 12,000, and certain higher in liver disease ^[61-71]. Blood product ought to get replaced once platelets area unit below 70,000/ μ L or clotting factor time is prolonged by quite four seconds, and/or a transjugular or laparoscopic approach chosen. Bayer and alternative anti-platelet agents ought to be stopped a minimum of per week before diagnostic test.

Liver

transplantation

The ultimate medical aid for liver disease and last stage disease is liver transplantation. The foremost recent survival information from the United Network of Organ Sharing (UNOS) indicates a one year survival of 83%, a five year survival of 70% and an eight year survival of 61% ^[72-83]. Survival is best in patients UN agency are reception at the time of transplant compared to people who are within the hospital or within the intensive care unit. A good advance in liver transplantation has been the advance in immunological disorder regimens in order that homograft loss from rejection is currently comparatively rare ^[83-91]. The most important problems that stay within the care of the patient post [liver transplantation](#) are repeated unwellness within the transplant, notably HCV, and long-term consequences of immunological disorder agents like high blood pressure, symptom and nephritic unwellness ^{[92-}

100].

CONCLUSION

The prevalence of cirrhosis of the liver is above antecedently calculable. Several cases could also be unknown, and over 0.5 square measure doubtless preventable by dominant polygenic disorder, alcoholism abuse, and hepatitis. Public health efforts can measure required cutting back of this unwellness burden, significantly among racial/ethnic minorities and people at lower socioeconomic standing.

Cirrhosis remains a standard liver pathology and alcohol was found to be a standard etiology. Quantity of alcohol consumption measure directly associated with cirrhosis of the liver. The classical microscopic feature was loss of design, pathology and portal triadities. Thus a public awareness would like of associate hour to avoid such dreadful unwellness that is totally preventable by straightforward traveller from alcohol in contrast to different etiologies which can need vaccination antiviral medical aid, frequent iron levels, accelerator levels and liver diagnostic assay to observe current unwellness method.

REFERENCES

1. Reich H, et al. Laparoscopic excision of benign liver lesions. *Obstet Gynecol.* 1991;78:956-958.
2. Hashizume M, et al. Laparoscopic hepatic resection for hepatocellular carcinoma. *Surg Endosc.* 1995;9:1289-1291.
3. Kaneko H, et al. Laparoscopic liver resection of hepatocellular carcinoma. *Am J Surg.* 2005;189:190-194.
4. Cherqui D, et al. Laparoscopic liver resection for peripheral hepatocellular carcinoma in patients with chronic liver disease: midterm results and perspectives. *Ann Surg.* 2006;243:499-506.
5. Noguera JF, et al. Transvaginal liver resection (NOTES) combined with mini laparoscopy. *Rev Esp Enferm Dig.* 2008;100:411-415.
6. Pearl JP and Ponsky JL. Natural orifice transluminal endoscopic surgery: a critical review. *J Gastrointest Surg.* 2008;12:1293-1300.
7. Auyang ED, et al. Human NOTES cholecystectomy: transgastric hybrid technique. *J Gastrointest Surg.* 2009;13:1149-1150.
8. Ponsky TA. Single port laparoscopic cholecystectomy in adults and children: tools and techniques. *J Am Coll Surg.* 2009;209:e1-6.
9. Roberts KE, et al. Single-incision laparoscopic cholecystectomy: a surgeon's initial experience with 56 consecutive cases and a review of the literature. *J Gastrointest Surg.* 2010;14:506-510.
10. Kirschniak A, et al. Transumbilical single-incision laparoscopic cholecystectomy: preliminary experiences. *Surg Laparosc Endosc Percutan Tech.* 2009;19: 436-438.
11. Targarona EM, et al. Single-port access: a feasible alternative to conventional laparoscopic splenectomy. *Surg Innov.* 2009;16: 348-352.
12. Muensterer OJ, et al. Single-incision laparoscopic pyloromyotomy: initial experience. *Surg Endosc.* 2010;24: 1589-1593.

13. Saber AA and El-Ghazaly TH. Early experience with SILS port laparoscopic sleeve gastrectomy. *Surg Laparosc Endosc Percutan Tech.* 2009;19: 428-430.
14. Florianczyk G . Metallothionein and its role in metal regulation. *Journal of Pre-Clinical and Clinical Research (JPCCR).* 2007;1: 16-18.
15. Itoh S, et al. Novel mechanism for regulation of extracellular SOD transcription and activity by copper: role of antioxidant-1. *Free Radic Biol Med.* 2009;46:95-104.
16. Florianczyk G . Trace elements as constituents of antioxidative proteins. *Journal of Pre-Clinical and Clinical Research (JPCCR).* 2008;2:25-27.
17. Bertinato J and L'Abbé MR. Maintaining copper homeostasis: regulation of copper-trafficking proteins in response to copper deficiency or overload. *J Nutr Biochem.* 2004;15:316-322.
18. Trumbo P, et al. Dietary reference intakes: vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. *J Am Diet Assoc.* 2001;101:294-301.
19. Gollan JL and Zucker SD. A new voyage of discovery: transport through the hepatocyte. *Trans Am Clin Climatol Assoc.* 1996;107:48-55.
20. De Feo CJ, et al. A structural perspective on copper uptake in eukaryotes. *Biometals.* 2007;20:705-716.
21. Moller S, et al. Pathogenetic background for treatment of ascites and hepatorenal syndrome. *Hepatology International.* 2008;2:416-428.
22. Naeije R. Hepatopulmonary syndrome and portopulmonary hypertension. *Swiss Med Wkly.* 2003;133:163-169.
23. Bosch J, et al. The management of portal hypertension: rational basis, available treatments and future options. *J Hepatol.* 2008;48:S68-S92.
24. Roberts S, et al. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. *Clin Gastroenterol Hepatol.* 2007;5:932-937.
25. Kumar M, et al. Hepatic venous pressure gradient as a predictor of fibrosis in chronic liver disease because of hepatitis B virus. *Liver Int.* 2008;28:690-698.
26. Ripoll C, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. *Gastroenterology.* 2007;133:481-488.
27. Qamar AA, et al. Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosis. *Hepatology.* 2008;47:153-159.
28. Castéra L, et al. Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and noninvasive scores. *J Hepatol.* 2009;50:59-68.
29. Bureau C, et al. Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease. *Aliment Pharmacol Ther.* 2008;27:1261-1268.
30. Shibayama Y and Nakata K. Localization of increased hepatic vascular resistance in liver cirrhosis. *Hepatology.* 1985;5:643-648.

31. Kreaden DA, et al. Collagenisation of the Disse space in alcoholic liver disease. *Gut*. 1979;20:673-679.
32. Langer DA and Shah VH. Nitric oxide and portal hypertension: interface of vasoreactivity and angiogenesis. *J Hepatol*. 2006;44:209-216.
33. Garcia-Tsao and Guadalupe. Portal hypertension. *Current Opinion in Gastroenterology*. 2006;22:254-262.
34. Rekvig OP and Van der Vlag J. The pathogenesis and diagnosis of systemic lupus erythematosus: still not resolved. *Semin Immunopathol*. 2014;36:301-311.
35. Yu C, et al. Diagnostic criteria for systemic lupus erythematosus: a critical review. *J Autoimmun*. 2014;48:10-3.
36. Efe C, et al. Autoimmune liver disease in patients with systemic lupus erythematosus: a retrospective analysis of 147 cases. *Scand J Gastroenterol*. 2011;46:732-737.
37. De Santis M, et al. Liver abnormalities in connective tissue diseases. *Best Pract Res Clin Gastroenterol*. 2013;27:543-551.
38. Runyon BA, et al. The spectrum of liver disease in systemic lupus erythematosus. Report of 33 histologically proved cases and review of the literature. *Am J Med*. 1980;69:187-194.
39. Heyman SN, et al. Autoimmune cholangiopathy associated with systemic lupus erythematosus. *Liver*. 2002;22:102-106.
40. Irving KS, et al. A comparison of autoimmune liver disease in juvenile and adult populations with systemic lupus erythematosus-a retrospective review of cases. *Rheumatology*. 2007;46:1171-1173.
41. Chowdhary VR, et al. Liver involvement in systemic lupus erythematosus: case review of 40 patients. *J Rheumatol*. 2008;35:2159-2164.
42. Her M, et al. Liver enzyme abnormalities in systemic lupus erythematosus: a focus on toxic hepatitis. *Rheumatol Int*. 2011;31:79-84.
43. Takahashi A, et al. Clinical features of liver dysfunction in collagen diseases. *Hepatol Res*. 2010;40:1092-1097.
44. Piga M, et al. Liver involvement in systemic lupus erythematosus: incidence, clinical course and outcome of lupus hepatitis. *Clin Exp Rheumatol*. 2010;28:504-510.
45. González LA, et al. Primary biliary cirrhosis/autoimmune hepatitis overlap syndrome developing in a patient with systemic lupus erythematosus: a case report and review of the literature. *Lupus*. 2011;20:108-111.
46. Madden AM, et al. Taste perception in cirrhosis: its relationship to circulating micronutrients and food preferences. *Hepatology*. 1997;26:40-48.
47. Ma Z, et al. Differential effects of jaundice and cirrhosis on beta-adrenoceptor signaling in three rat models of cirrhotic cardiomyopathy. *J Hepatol*. 1999;30:485-491.
48. Caregaro L, et al. Malnutrition in alcoholic and virus-related cirrhosis. *Am J Clin Nutr*. 1996;63:602-609.

49. Campillo B, et al. Evaluation of nutritional practice in hospitalized cirrhotic patients: results of a prospective study. *Nutrition*. 2003;19:515-521.
50. Lautz HU, et al. Protein-calorie malnutrition in liver cirrhosis. *ClinInvestig*. 1992;70:478-486.
51. Sobhonslidsuk A, et al. Impact of liver cirrhosis on nutritional and immunological status. *J Med Assoc Thai*. 2001;84:982-988.
52. Grant A and Neuberger J. Guidelines on the use of liver biopsy in clinical practice. *Gut* 45. 1999;(Suppl4):IV11V11.
53. Rösch J, et al. Transjugular approach to liver biopsy and transhepatic cholangiography. *N. Engl. J. Med*. 1973;5:227-31.
54. Silva MA, et al. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis". *Gut* . 2008;11:1592-1596.
55. Janes Lindor KD . Outcome of patients hospitalized for complications after outpatient liver biopsy .*Ann Intern Med* 118. 1993;2:96-8.
56. Pasha, et al. Cost-effectiveness of ultrasound-guided liver biopsy. *Hepatology* . 1998;5:1220-1226.
57. Liver Biopsy
58. Gilmore, et al. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. *Gut* . 1995;3:437- 41.
59. Strassburg and Manns MP. Approaches to liver biopsy techniques-revisited. *Semin Liver Dis*. 2006;4:318-27.
60. Froehlich et al. Practice and complications of liver biopsy. Results of a nationwide survey in Switzerland. *Dig Dis Sci*. 1993;8:1480-4.
61. Regev A, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection". *Am. J. Gastroenterol*. 2002;10:2614-8.
62. Agence Nationale d'Accréditation. Consensus conference. Treatment of hepatitis C. *Gastroenterol. Clin. Biol*. 2002;26:303-320.
63. . Manning DS and Afdhal NH. Diagnosis and quantitation of fibrosis. *Gastroenterology*. 2008;134:1670-81.
64. <http://www.oneliver.com/scientific-publications.html>
65. Poynard T, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. *Comp Hepatol*. 2004;3:8.

66. Castéra L, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis. *Ann Intern Med.* 2005;132:444-450.
67. Talreja DR, et al. Constrictive pericarditis in 26 patients with histologically normal pericardial thickness. *Circulation.* 2003;108:1852-1857.
68. Little WC and Freeman GL. Pericardial disease. *Circulation.* 2006;113:1622-1632.
69. Ariyoshi T, et al. Surgical experience with chronic constrictive pericarditis. *Gen Thorac Cardiovasc Surg.* 2012;60:796-802.
70. Lin Y, et al. Treating constrictive pericarditis in a chinese single-center study: a five-year experience. *Ann Thorac Surg.* 2012;94:1235-1240.
71. Yoneda M, et al. Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. *Radiology.* 2010;256:640-647.
72. Beckmann S, et al. Weight gain, overweight and obesity in solid organ transplantation-a study protocol for a systematic literature review. *Syst Ver.* 2015;4:1-8.
73. Saab S, Lalezari D, Pruthi P, Alper T, Tong MJ (2015) The impact of obesity on patient survival in liver transplant recipients: a meta-analysis. *Liver Int* 35:164-170.
74. Schutz T, et al. Weight gain in long-term survivors of kidney or liver transplantation-Another paradigm of sarcopenic obesity? *Nutrition.* 2012;28:378-383.
75. Parolin MB, et al. Terapianutricional no transplante hepático. *Arquivos de Gastroenterologia, São Paulo.* 2002;39:114-122.
76. Sims FH and Horn C. Some observations on Powell's methods for the determination of serum bilirubin. *Am J Clin Pathol.* 1958;29:412-417.
77. Henry JR, et al. Revised spectrophotometric methods for the determination of glutamic-oxaloacetic transaminase, glutamic-pyruvic transaminase, and lactic acid dehydrogenase. *Am J Clin Pathol.* 1960;34:381-398.
78. Bessey OA, et al. A method for the rapid determination of alkaline phosphatase with five cubic millimeters of serum. *J Biol Chem.* 1946;164: 321-329.
79. Ellman GL, et al. A new and rapid colorimetric determination of acetylcholinesterase activity. *Biochem.*

- Pharmacol. 1961;7:88-95.
80. Gornall AG, et al. Determination of serum proteins by means of biuret reaction. *J Biol Chem.* 1949;177:751-766.
81. Doumas BT, et al. Albumin standard and the measurement of serum albumin with bromocresol green. *Clin Chim Acta.* 1971;31:87-96.
82. Kaplan MM. Laboratory Tests. In: Schiff L, Schiff ER. *Diseases of the Liver*, Philadelphia: Lippincott IB. 1987:219-260.
83. International Federation of Clinical Chemistry-IFCC (1980).
84. World Health Organization-WHO. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. Geneva: World Health Organization, Technical Report Series. 1998:894.
85. Lipschitz DA. Screening for nutritional status in the elderly. *Primary Care.* 1994;21:55-57.
86. Blackburn GL and Thornton PA. Nutritional assessment of the hospitalized patients. *Med Clin North Am.* 1979;63:1103-1115.
87. Frisancho AR. New norms of upper limb fat and muscle areas for assessment of nutritional status. *Am J Clin Nutr.* 1981;34:2540-2545.
88. Frisancho AR. Anthropometric standards for the assessment of growth and nutritional status. Ann Arbor: The University of Michigan Press. 1990:48-53.
89. US Department of Health and Human Services. Centers for Disease Control and Prevention. National Center for Health Statistics. Anthropometric reference data for children and adults: United States, 1988-1994. *Vital and Health Statistics.* 2009;11: 249.
90. Stegall MD, et al. Metabolic complications after liver transplantation. Diabetes, hypercholesterolemia, hypertension, and obesity. *Transplantation.* 1995;60:1057-1060.
91. Richards J, et al. Weight gain and obesity after liver transplantation. *TransplInt.* 2005;18:461-466.
92. Anastácio LR, et al. Overweight in liver transplant recipients. *Rev Col Bras Cir.* 2013;40:502-507.
93. Nishida C, et al. Body fat distribution and non-communicable diseases in populations: overview of the 2008 WHO Expert Consultation on Waist Circumference and Waist-Hip Ratio. *Eur J Clin Nutr.* 2010;64:2-5.

94. Reichman TW, et al. Weighing the risk: Obesity and outcomes following liver transplantation. *World J Hepatol.* 2015;7:1484-1493.
95. Da Silva Alves V, et al. Nutritional status, lipid profile and HOMA-IR in post-liver transplant patients. *NutrHosp.* 2014;29:1154-1162.
96. Llamas L, et al. Values of the phase angle by bioelectrical impedance; nutritional status and prognostic value. *NutrHosp.* 2013;28:286-295.
97. Burra P, et al. Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry). *Am J Transplant.* 2010;10:138-148.
98. Burroughs AK, et al. 3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. *Lancet.* 2006;367:225-232.
99. Beresford TP and Everson GT. Liver transplantation for alcoholic liver disease: bias, beliefs, 6-month rule, and relapse--but where are the data? *Liver Transpl.* 2000;6:777-778.
100. Louvet A, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. *Hepatology.* 2007;45:1348-1354.